Headlines about MYOS RENS Technology (NASDAQ:MYOS) have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. MYOS RENS Technology earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned news articles about the company an impact score of 42.4052887204948 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
MYOS RENS Technology (NASDAQ:MYOS) traded down $0.13 on Friday, reaching $1.30. 79,910 shares of the company were exchanged, compared to its average volume of 175,943. The firm has a market capitalization of $8.25, a price-to-earnings ratio of -1.97 and a beta of 1.52. MYOS RENS Technology has a 52-week low of $1.12 and a 52-week high of $6.00.
MYOS RENS Technology (NASDAQ:MYOS) last posted its quarterly earnings results on Tuesday, November 14th. The company reported ($0.13) earnings per share for the quarter. The business had revenue of $0.16 million for the quarter. MYOS RENS Technology had a negative return on equity of 71.14% and a negative net margin of 941.41%.
Separately, ValuEngine upgraded shares of MYOS RENS Technology from a “strong sell” rating to a “sell” rating in a research report on Friday.
In other MYOS RENS Technology news, CEO Joseph Mannello purchased 20,336 shares of the stock in a transaction that occurred on Thursday, December 21st. The shares were purchased at an average cost of $1.46 per share, for a total transaction of $29,690.56. Following the completion of the transaction, the chief executive officer now owns 274,765 shares of the company’s stock, valued at approximately $401,156.90. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have purchased 112,024 shares of company stock worth $151,529 over the last 90 days. 45.70% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact MYOS RENS Technology (MYOS) Stock Price” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/04/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-myos-rens-technology-myos-stock-price.html.
MYOS RENS Technology Company Profile
MYOS RENS Technology Inc (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity.
Receive News & Ratings for MYOS RENS Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS RENS Technology and related companies with MarketBeat.com's FREE daily email newsletter.